Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Pipeline Review, H1 2017

  • ID: 4318717
  • Report
  • 25 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Gila Therapeutics Inc
  • Novo Nordisk A/S
  • XL-protein GmbH
  • MORE
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Pipeline Review, H1 2017

Summary:

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity, Epilepsy, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Gila Therapeutics Inc
  • Novo Nordisk A/S
  • XL-protein GmbH
  • MORE
  1. Introduction
  2. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
  3. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
  13. Gila Therapeutics Inc
  14. Novo Nordisk A/S
  15. XL-protein GmbH
  16. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
  17. Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. GT-001 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. GT-002 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. NN-9748 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. XL-310 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
  38. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
  39. Featured News & Press Releases
  40. Nov 09, 2012: Novel treatment strategies for epilepsy
  41. Appendix
  42. Methodology
  43. Coverage
  44. Secondary Research
  45. Primary Research
  46. Expert Panel Validation
  47. Contact Us
  48. Disclaimer
List of Tables
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Pipeline by Gila Therapeutics Inc, H1
  10. Pipeline by Novo Nordisk A/S, H1
  11. Pipeline by XL-protein GmbH, H1
  12. Dormant Projects, H1
List of Figures
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Molecule Types, H1
  6. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Gila Therapeutics Inc
  • Novo Nordisk A/S
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll